Blood pressure drug (Candesartan cilexetil) shows surprising power against MRSA

Scientists have identified an existing drug (Candesartan cilexetil) that can impair MRSA’s survival mechanisms. The discovery hints at a new approach to combating antibiotic-resistant infections without developing entirely new antibiotics. Antibiotic-resistant bacteria continue to outpace modern medicine, causing more than 2.8 million infections and over 35,000 deaths each year in the US alone. Among the most concerning is methicillin-resistant Staphylococcus aureus, or MRSA. Once largely confined to hospitals, MRSA now spreads in communities as well, causing skin infections, pneumonia, and even life-threatening bloodstream infections. A new study published in Nature Communications suggests an unexpected new approach. Researchers found that a widely prescribed blood pressure medication (Candesartan cilexetil, CC) may also help fight MRSA, pointing to a faster, more cost-effective path toward new treatments. The high cost and lengthy development time of new drugs led the team to explore using existing medications approved for other uses to treat bacterial infections. Instead of creating a new antibiotic from scratch, the research team investigated whether existing drugs could weaken bacteria in different ways. Their focus was on the bacterial cell membrane, a structure essential for survival that controls what enters and leaves the cell. They identified CC, a commonly used and inexpensive blood pressure drug, as a promising candidate. Because it is already approved and widely used, its safety profile is well understood, which could significantly shorten the timeline for clinical use in a new role. In laboratory tests, the researchers showed that the drug can combat MRSA by damaging its cell membrane and disrupting essential cellular processes. The treatment killed MRSA cells at multiple stages of growth and also reduced biofilm formation, which are clusters of bacteria that are especially hard to eliminate. @